Edward Fox

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Jeffrey Cohen, Alasdair Coles, Douglas L. Arnold et al. · The Lancet · 2012 · 1.2K citations

Rheumatology, Relapsing-remitting Multiple Sclerosis, Immunology +8

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Alasdair Coles, Cary Twyman, Douglas L. Arnold et al. · The Lancet · 2012 · 1.2K citations · Full text

Immunology, Clinical Trials, Neurological Progress +4

Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial

Anthony Traboulsee, Benjamin Greenberg, Jeffrey L. Bennett et al. · The Lancet Neurology · 2020 · 456 citations · Full text

Satralizumab Monotherapy, Placebo-controlled Phase 3, Ophthalmology +4

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis

Amit Bar‐Or, Jonathan Calkwood, Cathy Chognot et al. · Neurology · 2020 · 332 citations · Full text

Alemtuzumab CARE-MS II 5-year follow-up

Alasdair Coles, Jeffrey Cohen, Edward Fox et al. · Neurology · 2017 · 273 citations · Full text